"","name","presenterFirst","presenterLast","institution","city","country","title","lat","lng","category","sage","moa"
"1","639","Frank","Loganzo","Pfizer Oncology","Pearl River","United States","The first ACT: an efficient data tracking and sharing tool for ADC and linker-payload development",41.0589855,-74.0218063,"BIOINFORMATICS AND SYSTEMS BIOLOGY","ADC",NA
"2","731","Xiu Fen","Liu","NIH","Bethesda","United States","Actinomycin D enhanced immunotoxin RG7787 killing of cancer cells",38.984652,-77.0947092,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"3","790","Rebecca","Bagley","Celldex Therapeutics, Inc.","Needham","United States","Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma",42.2809285,-71.2377548,"CLINICAL RESEARCH","ADC",NA
"4","835","Z. Alexander","Cao","Novartis","Cambridge","United States","The immune modulatory roles of IAP inhibitor, LCL161, and its connection to immune-checkpoint molecules",42.3736158,-71.1097335,"IMMUNOLOGY","small combo CPI","immune"
"5","872","Breanna","Brenneman","University of Virginia","Charlottesville","United States","Assessing and augmenting the immune response to glioblastoma using repurposed pharmaceuticals",38.0293059,-78.4766781,"IMMUNOLOGY","small combo CPI","immune"
"6","1194","Ruth","Davis","Tumor Biology Section, Head and Neck Surgery Branch, National Institutes of Deafness and Other Communication Disorders, National Institutes of Health","Bethesda","United States","Targeting immunosuppressive myeloid cells in oral cavity cancer with the PI3K&#948;/&#947; isoform inhibitor duvelisib",38.9607587,-77.1155894,"IMMUNOLOGY","small","immune"
"7","1221","Sanna","Rosengren","Halozyme Therapeutics","San Diego","United States","PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer",32.715738,-117.1610838,"IMMUNOLOGY","small combo CPI","immune"
"8","1311","Jeff","Hsu","Pharmacyclics LLC, an AbbVie Company","Sunnyvale","United States","Ibrutinib enhances antitumor activity in solid tumors when combined with checkpoint inhibitors",37.36883,-122.0363496,"IMMUNOLOGY","small combo CPI","immune"
"9","1330","Manfred","Kraus","Pfizer","San Diego","United States","PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors",32.715738,-117.1610838,"IMMUNOLOGY","small combo CPI","immune"
"10","1336","Yujun","Huang","Pharmacyclics LLC, an AbbVie Company","Sunnyvale","United States","The BTK inhibitor ibrutinib modulates T cell immunity in mouse models and in differentiated human T cells",37.36883,-122.0363496,"IMMUNOLOGY","small","oncogenic kinases"
"11","1386","Andrew","Stiff","The Ohio State University","Columbus","United States","Ibrutinib, a BTK inhibitor, impairs the generation and function of myeloid derived suppressor cells",39.9611755,-82.9987942,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"12","1473","Sangeeta","Goswami","MD Anderson Cancer Center","Katy","United States","Epigenetic changes in T cells in response to immune checkpoint blockade",29.7857853,-95.8243956,"IMMUNOLOGY","small combo CPI","epigenetics"
"13","1615","Andrew","Leishman","MedImmune","Cambridge","United Kingdom","Local immune activation resulting in tumor growth inhibition with MEDI9197 - an intratumorally administered TLR7/8 agonist",52.205337,0.121817,"IMMUNOLOGY","small combo CPI","immune"
"14","1838","Nandini","Rudra-Ganguly","Agensys Inc., an Affiliate of Astellas Pharma Inc.","Santa Monica","United States","AGS62P1, a novel site-specific antibody drug conjugate targeting FLT3 exhibits potent anti-tumor activity regardless of FLT3 kinase activation status",34.0194543,-118.4911912,"IMMUNOLOGY","ADC",NA
"15","1842","Kun-Yu","Teng","The Ohio State University","Columbus","United States","Inhibition of liver inflammation and tumorigenesis by blocking Ccl2-Ccr2 axis in a mouse model",39.9611755,-82.9987942,"IMMUNOLOGY","small","immune"
"16","1901","Jennifer","McQuade","UT MD Anderson Cancer Center","Houston","United States","A phase II trial of high-dose Interleukin-2 (HDIL-2) with recombinant MAGE-A3 protein combined with adjuvant system AS15 in patients with unresectable or metastatic melanoma",29.7604267,-95.3698028,"IMMUNOLOGY","small","immune"
"17","2050","Stephen","Shuttleworth","Karus Therapeutics Ltd","Abingdon, Oxfordshire","United Kingdom","KA2237 and KA2507: Novel, oral cancer immunotherapeutics targeting PI3K-p110&#946;/p110&#948; and HDAC6 with single-agent and combination activity",51.67078,-1.2879529,"IMMUNOLOGY","small combo other","leucocyte kinases"
"18","2178","Naoto","Nishii","Department of Molecular Immunology, Tokyo Medical and Dental University","Tokyo","Japan","Combined treatment with PD-L1 blockade and a TLR7/8 agonist dramatically enhances antitumor immunity",35.7090259,139.7319925,"IMMUNOLOGY","small combo CPI","immune"
"19","2301","Rachelle","Dillon","Viventia Bio Inc","Winnipeg","Canada","deBouganin conjugated to trastuzumab overcomes multiple mechanisms of T-DM1 drug resistance",49.8997541,-97.1374937,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"20","2302","Shilpa","Chooniedass","Viventia Bio Inc","Winnipeg","Canada","VB7-756: a Her2-specific diabody armed with deBouganin, a plant toxin with a distinct MOA",49.8997541,-97.1374937,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"21","2499","Takahiro","Yamazaki","Gustave Roussy Cancer Campus","VILLEJUIF","France","LTX-315, an oncolytic peptide, increases anticancer immunity mediated by CTLA4 blockade in an interleukin-2 receptor beta-chain-dependent manner",48.792716,2.359279,"IMMUNOLOGY","small combo CPI","immune"
"22","2534","Paul","Sondel","University of Wisconsin","Madison","United States","Effective <i>in situ</i> immunization via local radiation therapy (RT) and tumor-specific immunocytokine (IC): Suppression from distant tumor is blocked by RT or Treg-depleting CTLA-4 antibody",43.0730517,-89.4012302,"IMMUNOLOGY","small combo CPI","immune"
"23","2540","Stephen","Shaw","Agalimmune Ltd","Sandwich","United Kingdom","AGI-134: a fully synthetic alpha-Gal glycolipid that prevents the development of distal lesions and is synergistic with an anti-PD-1 antibody in a mouse melanoma model",51.274017,1.337427,"IMMUNOLOGY","small combo CPI","immune"
"24","2557","Aradhana","Tiwari","New York Medical College","Elsmford","United States","Antibody drug conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) exhibit enhanced cell death targeted to CD79b+ Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL)",41.0550969,-73.8201337,"IMMUNOLOGY","ADC",NA
"25","2855","Genevieve","Weir","Immunovaccine Inc.","Halifax","Canada","Multimodal therapy with a potent vaccine, metronomic cyclophosphamide and anti-PD-1 enhances immunotherapy of advanced tumors by increasing activation and clonal expansion of tumor infiltrating T cells",44.6488625,-63.5753196,"IMMUNOLOGY","small combo CPI","chemotherapy"
"26","2986","Yan","Wang","Verastem","Needham","United States","FAK/PYK2 inhibition enhances immune checkpoint inhibitor efficacy",42.2809285,-71.2377548,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"27","3057","Dirk","Zboralski","NOXXON Pharma","Berlin","Germany","CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T-cell infiltration in tumor-stroma spheroids and synergizes with PD-1 immune checkpoint blockade",52.5200066,13.404954,"IMMUNOLOGY","small combo CPI","immune"
"28","3143","Gilad","Kaplan","National Cancer Institute, NIH","Bethesda","United States","Engineering next-generation anti-CD25 immunotoxins with improved cytotoxic activity and low immunogenicity",38.984652,-77.0947092,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"29","3213","Øystein","Rekdal","Lytix Biopharma","Oslo","Norway","The oncolytic peptide LTX-315 enhances tumor-specific immune responses and tumor regression in murine 4T1 breast cancer when combined with doxorubicin",59.9138688,10.7522454,"IMMUNOLOGY","small combo other","immune"
"30","3298","Heiyoun","Jung","ChemoCentryx","Mountain View","United States","Combination therapy of chemokine receptor inhibition plus PD-L1 blockade potentiates antitumor effects in a murine model of breast cancer",37.3860517,-122.0838511,"IMMUNOLOGY","small combo CPI","immune"
"31","3374","Laura","Carter","Lycera Corp","Ann Arbor","United States","ROR&#947; agonists regulate immune checkpoint receptors to enhance anti-tumor immunity",42.2808256,-83.7430378,"IMMUNOLOGY","small","immune"
"32","3381","Maria","Jaramillo","National Research Council of Canada","Montréal","Canada","Assays for the selection and functional characterization of antibody-drug conjugates at the National Research Council of Canada",45.5016889,-73.567256,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"33","3431","Katherine","Chiappinelli","The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine","Baltimore","United States","Inhibiting DNA methylation causes an interferon response in cancer cells via endogenous retroviruses and recruits immune cells to the tumor microenvironment to sensitize to immune therapy",39.2903848,-76.6121893,"IMMUNOLOGY","small combo CPI","epigenetics"
"34","3515","Jodi","McKenzie","The University of Texas MD Anderson Cancer Center","Houston","United States","Enhancing the antitumor efficacy of immunotherapy by using the topoisomerase I inhibitor MM398",29.7604267,-95.3698028,"IMMUNOLOGY","small combo CPI","chemotherapy"
"35","3530","Holly","Koblish","Incyte Corporation","Wilmington","United States","The BET inhibitor INCB054329 enhances the activity of checkpoint modulation in syngeneic tumor models",39.7390721,-75.5397878,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"36","3585","Meredith","Stone","Johns Hopkins School of Medicine","Baltimore","United States","Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: implications for response to immune checkpoint therapy",39.2903848,-76.6121893,"IMMUNOLOGY","small combo CPI","epigenetics"
"37","3637","Stephen","Willingham","Corvus Pharmaceuticals","Burlingame","United States","The adenosine A2A receptor antagonist CPI-444 blocks adenosine-mediated T-cell suppression and exhibits antitumor activity alone and in combination with anti-PD-1 and anti-PD-L1",37.5778696,-122.34809,"IMMUNOLOGY","small combo CPI","immune"
"38","3654","Dai","Liu","Medical University of South Carolina","Charleston","United States","Development of a successful combination therapy for hepatocellular cancer by targeting Treg and PD-1",32.7764749,-79.9310512,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"39","3664","Darren","Shafren","Viralytics Limited","New Lambton","Australia","Elevated immune activity following an anticancer combination therapy of a novel oncolytic immunotherapeutic agent, CAVATAK (Coxsackievirus A21), and immune checkpoint blockade",-32.9221931,151.7142905,"IMMUNOLOGY","small combo CPI","immune"
"40","3796","Hong","Zhang","Concortis Biosystem","San Diego","United States","Development of anti-5T4 antibody-drug conjugates, ZV05-ADCs for targeted cancer therapy in different type of cancers",32.715738,-117.1610838,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"41","3806","David","Briere","Mirati Therapeutics, Inc.","San Diego","United States","The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations",32.715738,-117.1610838,"IMMUNOLOGY","small combo CPI","epigenetics"
"42","3815","Douglas","Lazarus","Cerulean Pharma, Inc.","Walthem","United States","CRLX101, an investigational nanoparticle-drug conjugate of camptothecin, demonstrates synergy with immunotherapy agents in preclinical models",42.3764852,-71.2356113,"IMMUNOLOGY","small combo ADC","immune"
"43","3967","Jill","Smith","Georgetown University","Washington","United States","Combination therapy with immune checkpoint inhibitor and CCK-receptor blockade increases survival of pancreatic cancer",38.9071923,-77.0368707,"IMMUNOLOGY","small combo CPI","immune"
"44","3989","Michael","Xiao","Brigham Young University","Pleasant Grove","United States","Killing cancer one cell at a time: Development and characterization of a novel antibody drug conjugate",40.3641184,-111.73854,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"45","4005","Idit","Sagiv-Barfi","Stanford University","Stanford","United States","In situ vaccination with TLR9 agonist and anti-Ox40 antibody is sufficient to induce abscopal responses even in mice with spontaneous oncogene-driven tumors.",37.424106,-122.1660756,"IMMUNOLOGY","small combo CPI","immune"
"46","4018","Xiangliang","Yuan","The University of Texas M. D. Anderson Cancer Center","Houston","United States","Immunogenic chemotherapy synergize PD-1 blockade by enhancing dendritic cells infiltration in triple-negative breast cancer (TNBC)",29.7604267,-95.3698028,"CLINICAL RESEARCH","small combo CPI","chemotherapy"
"47","4022","Jeffrey","Wallin","Genentech, Inc.","San Francisco","United States","Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma",37.7749295,-122.4194155,"CLINICAL RESEARCH","small combo CPI","chemotherapy"
"48","4045","Cristiana","Guiducci","Dynavax Technologies","Berkeley","United States","Intratumoral treatment with a highly interferogenic TLR9 agonist reverts tumor escape from PD-1 blockade",37.8715926,-122.272747,"IMMUNOLOGY","small combo CPI","immune"
"49","4228","Anna","Dimberg","Uppsala University","Uppsala","Sweden","Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment",59.8585638,17.6389267,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"50","4266","Sylvie","Maubant","Oncodesign S.A.","Dijon","France","Antitumor activity of the oncolytic peptide LTX-315 in syngeneic tumor models",47.322047,5.04148,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small combo CPI","immune"
"51","4286","Hongwei","Chen","University of Michigan","Ann Arbor","United States","Boosting immunotherapy via stealthy nanoparticle-mediated photothermal therapy",42.2808256,-83.7430378,"IMMUNOLOGY","small combo CPI","immune"
"52","4362","Mototsugu","Watanabe","Okayama University Graduate School of Medicine","Okayama","Japan","Metformin improves multiple cytokine producing ability of exhausted peripheral CD8+ T cells of cancer patients",34.6551456,133.9195019,"IMMUNOLOGY","small","other"
"53","4406","Michael","Kulke","Heidelberg Pharma GmbH","Ladenburg","Germany","CD269 - A promising target for amanitin based ADCs",49.4739759,8.6077464,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"54","4545","David","Schaer","Eli Lilly and Company","New York","United States","Targeting the TGF&#946; pathway with galunisertib, a small molecule inhibitor of TGF&#946;RI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition.",40.7127837,-74.0059413,"CLINICAL RESEARCH","small combo CPI","immune"
"55","4554","Qun","Li","Shanghai Denovo Pharmatech","Zhangjiang New Area, Shanghai","China","Discovery of novel and potent inhibitors of indoleamine-2,3-dioxygenase (IDO1) for cancer immunotherapy",31.2020359,121.6185532,"IMMUNOLOGY","small","immune"
"56","4575","Robert","Leone","Sidney Kimmel Comprehensive Cancer Research Center, Johns Hopkins University School of Medicine","Baltimore","United States","Adenosine A2a receptor blockade as a means of enhancing immune checkpoint inhibition and adoptive T-cell therapy",39.2903848,-76.6121893,"IMMUNOLOGY","small combo CPI","immune"
"57","4633","Jingli","Zhang","National Cancer Institute","Bethesda","United States","The reduced immunogenicity anti-mesothelin immunotoxin RG7787 in combination with nab-paclitaxel has significant anti-tumor efficacy against primary mesothelioma cell lines and patient derived mesothelioma tumor xenografts",38.984652,-77.0947092,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"58","4657","Kathryn","Fraser","Biothera","Eagan","United States","Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with &#945;PD-L1 treatment in vivo",44.8041322,-93.1668858,"IMMUNOLOGY","small combo CPI","immune"
"59","4717","Bryan","Smith","Deciphera Pharmaceuticals","Lawrence","United States","The highly specific CSF1R inhibitor DCC-3014 exhibits immunomodulatory and anti-invasive activities in cancer models",38.9716689,-95.2352501,"IMMUNOLOGY","small combo CPI","immune"
"60","4824","Rebecca","Arend","University of Alabama Birmingham","Birmingham","United States","Epigenetic induction of MHC-II pathway expression in murine ovarian cancer cell line",33.5206608,-86.80249,"IMMUNOLOGY","small","epigenetics"
"61","4878","Melissa","Works","Calithera Biosciences","South San Francisco","United States","Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response",37.654656,-122.4077498,"IMMUNOLOGY","small","immune"
"62","4916","Sharon","Friedlander","Karyopharm Therapeutics Inc","Newton","United States","Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity when combined with PD-1 blockade in a mouse model of colon cancer",42.3370413,-71.2092214,"CLINICAL RESEARCH","small combo CPI","other"
"63","5007","Caitlin","Lemke","University of Iowa","Iowa City","United States","Combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG ODN",41.6611277,-91.5301683,"CLINICAL RESEARCH","small combo CPI","immune"
"64","5066","Sandra","Demaria","Weill Cornell Medical College","New York","United States","Role of the PD-1/PDL-1 pathway in resistance of patients with metastatic breast cancer to treatment with radiotherapy and TGF&#946; neutralization",40.7127837,-74.0059413,"CLINICAL RESEARCH","small combo CPI","immune"
"65","5145","Garrett","Robinson","Molecular Templates Inc.","Georgetown","United States","MT-3724, an engineered toxin body targeting CD20 for non-Hodgkin&#8217;s lymphoma",30.6332618,-97.6779842,"IMMUNOLOGY","small","immune"
"66","5162","Matthew","Farren","Ohio State University - James Comprehensive Cancer Center","Columbus","United States","Selinexor, a selective inhibitor of nuclear export (SINE), enhances the in vivo efficacy of checkpoint blockade with antibodies targeting CTLA4 or PD-1/PD-L1 in melanoma",39.9611755,-82.9987942,"IMMUNOLOGY","small combo CPI","other"
"67","5182","Matt","Gross","Calithera Biosciences","South San Francisco","United States","Glutaminase inhibition with CB-839 enhances anti-tumor activity of PD-1 and PD-L1 antibodies by overcoming a metabolic checkpoint blocking T cell activation",37.654656,-122.4077498,"IMMUNOLOGY","small combo CPI","other"
"68","5225","Rajaa","El Meskini","Leidos Biomedical Research, Inc.","Frederick","United States","Preclinical model of human melanoma for evaluation of targeted drug treatment and for immunotherapy validation",39.4142688,-77.4105409,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"69","5255","Tina","Albershardt","Immune Design","Seattle","United States","Intratumoral expression of IL-12 from a dendritic cell-targeting chimeric lentiviral vector from the ZVex platform cures established tumors in multiple models and induces systemic anti-tumor responses",47.6062095,-122.3320708,"IMMUNOLOGY","small combo CPI","immune"
"70","5265","Tai","Wong","Peloton Therapeutics","Dallas","United States","PT2385, a novel HIF-2&#945; antagonist, combines with checkpoint inhibitor antibodies to inhibit tumor growth in preclinical models by modulating myeloid cells and enhancing T cell infiltration",32.7766642,-96.7969879,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"71","5267","Christopher","Thanos","Halozyme Therapeutics","San Diego","United States","Enzymatic depletion of adenosine by pegylated, engineered adenosine deaminase 2 (PEG-ADA2): A novel immunotherapeutic approach to treat solid tumors",32.715738,-117.1610838,"IMMUNOLOGY","small","immune"
"72","5296","Suresh","Kumar","Progenra, Inc.","Malvern","United States","Small molecule T-reg inhibitors for cancer immunotherapy",40.0362184,-75.5138118,"IMMUNOLOGY","small combo CPI","immune"
"73","5307","Sangeetha","Rajagopalan","Molecular Templates Inc.","Georgetown","United States","Next-generation engineered toxin bodies: CD38, PD-L1 and HER2 targeted ETBs",30.6332618,-97.6779842,"IMMUNOLOGY","small","immune"
"74","5313","Weiyi","Peng","M.D. Anderson Cancer Center","Houston","United States","Loss of PTEN promotes resistance to T cell-mediated immunotherapy",29.7604267,-95.3698028,"IMMUNOLOGY","small combo CPI","leucocyte kinases"
"75","5345","Olivier","De Henau","Memorial Sloan Kettering Cancer Center","New York","United States","Checkpoint blockade therapy is improved by altering the immune suppressive microenvironment with IPI-549, a potent and selective inhibitor of PI3K-gamma, in preclinical models",40.7127837,-74.0059413,"IMMUNOLOGY","small combo CPI","leucocyte kinases"
"76","5371","Sacha","Holland","Rigel Pharmaceuticals, Inc.","S. San Francisco","United States","Small molecule inhibitors of the anti-inflammatory TAM receptor MerTK",37.654656,-122.4077498,"IMMUNOLOGY","small","immune"
"77","5375","Alejandro","Villagra","The George Washington University","Falls Church","United States","HDAC6, new role as master regulator of PD-L1 and immune-related pathways",38.882334,-77.1710914,"IMMUNOLOGY","small combo CPI","epigenetics"
"78","5425","David","Goldenberg","Immunomedics, Inc.","Morris Plains","United States","Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors",40.8395922,-74.4818698,"IMMUNOLOGY","small combo ADC","oncogenic kinases"
"79","5439","Salvatore","Condello","Indiana University","Indianapolis","United States","Epigenetic priming potentiates immune checkpoints inhibitors in ovarian cancer",39.768403,-86.158068,"IMMUNOLOGY","small combo CPI","epigenetics"
"80","5505","Urs","Hagemann","Bayer AS","Oslo","Norway","A novel high energy alpha-pharmaceutical:<i> In vitro</i> and <i>in vivo </i>potency of a mesothelin-targeted thorium-227 conjugate (TTC) in a model of bone disease",59.9138688,10.7522454,"IMMUNOLOGY","ADC",NA
"81","5581","Natasha","Bodyak","Mersana Therapeutics","Cambridge","United States","Optimization of lead antibody selection for XMT-1522, a novel, highly potent HER2-targeted antibody-drug conjugate (ADC)",42.3736158,-71.1097335,"IMMUNOLOGY","ADC",NA
"82","5596","Saket","Agarwal","Progenra Inc","Malvern","United States","Cbl-b inhibitors as novel intra-cellular checkpoint inhibitors for cancer immunotherapy",40.0362184,-75.5138118,"CLINICAL RESEARCH","small","immune"
"83","5614","JaSeok Peter","Koo","Yale School of Medicine","New Haven","United States","Anti-cancer efficacy of the combination with immunomodulatory antibodies and MEK inhibitor for Kras mutation and p53 knockout driven lung cancer",41.308274,-72.9278835,"IMMUNOLOGY","small combo CPI","epigenetics"
"84","5627","Anda","Vlad","University of Pittsburgh, School of Medicine","Pittsburgh","United States","Chemo-induced biology of PD-L1 and <i>in vivo</i> combination immune therapy for ovarian cancer",40.4406248,-79.9958864,"IMMUNOLOGY","small combo CPI","chemotherapy"
"85","5633","James","Lorens","Department of Biomedicine, Center for Cancer Biomarkers, University of Bergen","Bergen","Norway","BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy",60.3912628,5.3220544,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"86","5665","Thu Le","Trinh","Moffitt Cancer Center","Tampa","United States","GPC3-specific chimeric antigen receptor T cell in combination with Sorafenib as a novel therapeutic treatment for hepatocellular carcinoma",27.950575,-82.4571776,"IMMUNOLOGY","small combo other","oncogenic kinases"
"87","5696","Luqun","Shen","University of Notre Dame","Notre Dame","United States","Developing a novel immunotoxin that targets cells overexpressing ErbB2",41.7001908,-86.2379328,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"88","5792","Andrew","Mckenzie","Crown Bioscience UK Ltd","Loughborough","United Kingdom","Immune competent syngeneic models demonstrate additive effects of combination strategies using checkpoint immunotherapy and inducers of immunogenic cell death (ICD)",52.772099,-1.206166,"IMMUNOLOGY","small combo CPI","chemotherapy"
"89","5863","Ashley","Orillion","Indiana University - Purdue University Indianapolis","Indianapolis","United States","The selective class I HDAC inhibitor entinostat enhances the antitumor effect of PD-1 inhibition in a syngeneic orthotopic murine model of renal cell carcinoma",39.768403,-86.158068,"IMMUNOLOGY","small combo CPI","epigenetics"
"90","5935","Leah","Mitchell","Tocagen","San Diego","United States","Combining Toca 511 and 5-fluorocytosine with &#945;PD-1 or &#945;CTLA-4 antibody significantly reduces tumor burden compared to either checkpoint inhibitor alone or in combination in a subcutaneous mouse glioma model",32.715738,-117.1610838,"IMMUNOLOGY","small combo CPI","immune"
"91","5950","Dewan Mohammed Sakib","Hossain","Merck Research Laboratories","Palo Alto","United States","Dinaciclib induces immunogenic cell death and enhances anti-PD-1 mediated tumor suppression",37.4418834,-122.1430195,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"92","6041","Elaine","Pinheiro","Merck & Co., Inc.","Kenilworth","United States","Preclinical combination strategies to enhance the efficacy of the anti-PD-1 antibody pembrolizumab",40.6764911,-74.2907032,"IMMUNOLOGY","small combo CPI","immune"
"93","6077","Darren","Cullinan","Washington University","Saint Louis","United States","Vaccination enhances anti-tumor immunity in ovarian cancer following repolarization of the tumor microenvironment with CCR2 blockade",38.6270025,-90.1994042,"IMMUNOLOGY","small","immune"
"94","6161","Tamas","Gonda","Columbia University","NC","United States","Hypomethylation therapy leads to immune polarization and improved efficacy of immunotherapy in transgenic model of pancreatic cancer",40.5977636,-74.0569617,"IMMUNOLOGY","small combo CPI","epigenetics"
"95","6384","Blake","Scott","Johns Hopkins University School of Medicine","Baltimore","United States","Inhibition of adenosine A2A receptor (A2AR) by CPI-444 enhances CD8+ T cell killing of a HER-2/neu expressing murine tumor",39.2903848,-76.6121893,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"96","6403","John","Langowski","Nektar Therapeutics","San Francisco","United States","Durable antitumor activity of the CD122-biased immunostimulatory cytokine NKTR-214 combined with immune checkpoint blockade",37.7749295,-122.4194155,"IMMUNOLOGY","small combo CPI","immune"
"97","6405","Laura","Glickman","Aduro Biotech, Inc.","Berkeley","United States","STING activation in the tumor microenvironment with a synthetic human STING-activating cyclic dinucleotide leads to potent anti-tumor immunity",37.8715926,-122.272747,"IMMUNOLOGY","small","immune"
"98","6481","Maureen","O'Connor-McCourt","Formation Biologics","Montreal","Canada","Development of a novel class of traps that potently block transforming growth factor-beta (TGF-beta) thereby counteracting TGF-beta mediated immunosuppression and promoting T-cell infiltration into tumors",45.5016889,-73.567256,"IMMUNOLOGY","small","immune"
"99","6608","Tyler","Hulett","Oregon Health & Science University","Portland","United States","Increased IgG antibody responses to neoepitope and native peptides containing high affinity domains for MHCI following combination cancer immunotherapy",45.5230622,-122.6764816,"IMMUNOLOGY","small","immune"
"100","6679","Marcia","Belvin","Genentech, Inc.","South San Francisco","United States","Effects of chemotherapeutic agents on the tumor immune microenvironment",37.654656,-122.4077498,"IMMUNOLOGY","small combo CPI","chemotherapy"
"101","6696","Marcia","Belvin","Genentech, Inc.","South San Francisco","United States","Effects of MAPK pathway inhibitors in the tumor immune microenvironment",37.654656,-122.4077498,"IMMUNOLOGY","small combo CPI","oncogenic kinases"
"102","410","Sara","Hurvitz","UCLA","Santa Monica","United States","Preclinical evaluation of targeting Notch-3 in breast cancer",34.0194543,-118.4911912,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"103","440","Bitha","Narayanan","Pfizer","Pearl River","United States","Creating a superior, site-specific anti-HER2 antibody-drug conjugate (NG-HER2 ADC) for treatment of solid tumors",41.0589855,-74.0218063,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"104","912","Yves","Baudat","SANOFI","vitry sur Seine","France","Characterization of a novel maytansinoid-antibody-drug conjugate targeting LAMP1 expressed at the surface of tumor cells",48.792001,2.39851,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"105","1183","Patrick","Burke","Seattle Genetics, Inc.","Bothell","United States","Optimal PEGylation of an auristatin linker provides ADCs with improved pharmacological properties",47.7623204,-122.2054035,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"106","1196","Patrick","Burke","Seattle Genetics, Inc.","Bothell","United States","Development of quaternary amine linkers for ADCs: Application to auristatin E and tubulysin",47.7623204,-122.2054035,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"107","1354","Robert","Kolakowski","Seattle Genetics","Bothell","United States","A novel linker to enable alcohol-containing payloads for the preparation of antibody-drug conjugates",47.7623204,-122.2054035,"CANCER CHEMISTRY","ADC",NA
"108","1415","Fu","Li","Seattle Genetics","Bothell","United States","Tumor associated macrophages can process antibody-drug conjugates and contribute to antitumor activity in preclinical xenograft models",47.7623204,-122.2054035,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"109","1423","Tim","Lewis","Seattle Genetics, Inc.","Bothell","United States","SGN-CD352A: A novel humanized anti-CD352 antibody-drug conjugate for the treatment of multiple myeloma",47.7623204,-122.2054035,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"110","1733","Manami","Shizuka","ImmunoGen, Inc.","Waltham","United States","Peptide-linked indolino-benzodiazepine DNA-alkylating agents for use in antibody-drug conjugates (ADCs)",42.3764852,-71.2356113,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"111","2902","Nicholas","Yoder","ImmunoGen, Inc.","Waltham","United States","Potent <i>in vivo</i> activity of site-specific indolino-benzodiazepine antibody-drug conjugates (ADCs) generated via engineered cysteine conjugation",42.3764852,-71.2356113,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"112","2926","Marc","Damelin","Pfizer, Inc.","Pearl River","United States","A novel PTK7-targeted antibody-drug conjugate eliminates tumor-initiating cells and induces sustained tumor regressions",41.0589855,-74.0218063,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"113","3149","Dilrukshi","Vitharana","ImmunoGen, Inc","Waltham","United States","<i>In vitro</i> and <i>in vivo</i> activity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent",42.3764852,-71.2356113,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"114","3212","James","Prudent","Centrose","Madison","United States","An anti-CD20 extracellular antibody-drug conjugate for the treatment of B-cell malignancies",43.0730517,-89.4012302,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"115","3274","Luke","Harris","ImmunoGen","Waltham","United States","<i>In vitro</i> and<i> in vivo</i> activity of site-specific antibody-drug conjugates (ADCs) with 2 and 4 maytansinoid molecules per antibody prepared through conjugation to SeriMabs (N-terminal serine engineered Abs)",42.3764852,-71.2356113,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"116","3686","Django","Sussman","Seattle Genetics","Bothell","United States","Preclinical combinations of the antibody-drug conjugate SGN-LIV1A with chemotherapies show increased activity",47.7623204,-122.2054035,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small combo ADC","chemotherapy"
"117","3775","Shweta","Singh","CytomX Therapeutics","South San Francisco","United States","Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas",37.654656,-122.4077498,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"118","3812","Monique","Balhorn","SHAL Technologies, Inc.","Livermore","United States","Metabolism studies of SH7139, a small molecule drug targeting B-cell malignancies overexpressing HLA-DR10, confirm its prodrug function",37.6818745,-121.7680088,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"119","3870","Bernadette","Marquez","Washington University School of Medicine","Maplewood","United States","Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer",38.6125521,-90.3245599,"TUMOR BIOLOGY","ADC",NA
"120","3900","Rodney","Balhorn","SHAL Technologies, Inc.","Livermore","United States","Inhibition of Rac1 GTPase activity by SH7139, a new drug candidate for non-Hodgkin&#8217;s lymphoma targeting HLA-DR10",37.6818745,-121.7680088,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"121","3994","Natalya","Bodyak","Mersana Therapeutics","Cambridge","United States","Discovery and preclinical development of a highly potent NaPi2b-targeted antibody-drug conjugate (ADC) with significant activity in patient-derived non-small cell lung cancer (NSCLC) xenograft models",42.3736158,-71.1097335,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"122","4348","Carl","Bialucha","Novartis Institutes for Biomedical Research","Arlington","United States","Targeting cadherin-6 (CDH6) with an antibody-drug conjugate for the treatment of ovarian and renal cancer.",42.4153925,-71.1564729,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"123","4539","Dorin","Toader","MedImmune LLC","Gaithersburg","United States","MEDI4276, a HER2-targeting antibody tubulysin conjugate, displays potent in<i> vitro </i>and <i>in vivo</i> activity in preclinical studies",39.1434406,-77.2013705,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"124","3719","Anthony","Cao","Seattle Genetics","Bothell","United States","Auristatin-based antibody drug conjugates activate multiple ER stress response pathways resulting in immunogenic cell death and amplified T-cell responses",47.7623204,-122.2054035,"IMMUNOLOGY","ADC",NA
"125","5140","Scott","Collins","Novartis Institutes for Biomedical Research","Cambridge","United States","In vivo activity of a novel CDH6 targeting antibody-drug conjugate, including population-scale ovarian PDX clinical trial",42.3736158,-71.1097335,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"126","5428","Renata","Sano","Children's Hospital of Philadelphia","Philadelphia","United States","A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma",39.9525839,-75.1652215,"CLINICAL RESEARCH","ADC",NA
"127","5702","Gail","Lewis Phillips","Genentech, Inc.","South San Francisco","United States","Preclinical development of 2nd generation HER2-directed antibody-drug conjugates",37.654656,-122.4077498,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"128","5755","Juniper","Scribner","MacroGenics, Inc.","South San Francisco","United States","Anti-B7-H3 antibody-drug conjugates as potential therapeutics for solid cancer",37.654656,-122.4077498,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"129","5804","Leslie","Sharp","BioAtla","San Diego","United States","Novel conditionally active biologic anti-Axl antibody-drug conjugate demonstrates anti-tumor efficacy and improved safety profile",32.715738,-117.1610838,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"130","6042","David","Corcoran","King's College London","London","United Kingdom","Low molecular weight pyrrolobenzodiazepine (PBD) monomers have potent cytotoxicity in haematological malignancies",51.5073509,-0.1277583,"CANCER CHEMISTRY","ADC",NA
"131","6352","Calin","Dumitru","TSRI","San Diego","United States","Meditope enablement and structural analysis of anti-CD33 antibodies",32.715738,-117.1610838,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"132","6663","Gang","Chen","Concortis Biosystems","san diego","United States","A novel c-Met targeting antibody drug conjugate for NSCLC",32.715738,-117.1610838,"CANCER CHEMISTRY","ADC",NA
"133","1329","Alan","Wise","IOmet Pharma Ltd","Edinburgh","United Kingdom","Pre-clinical development of next generation inhibitors of the enzymes indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase as cancer immunotherapies",55.953252,-3.188267,"TUMOR BIOLOGY","small","immune"
"134","3190","Vadivel","Ganapathy","Texas Tech University Health Science Center","Lubbock","United States","Repurposing the FDA-approved drug carbidopa to treat human cancers",33.5778631,-101.8551665,"MOLECULAR AND CELLULAR BIOLOGY, GENETICS","small","immune"
"135","4799","Daqing","Wang","Idera Pharmaceuticals, Inc.","Cambridge","United States","Creating the tumor microenvironment for effective immunotherapy: Antitumor activity of intratumoral IMO-2125, a TLR9 agonist is further enhanced by inhibition of indoleamine-pyrrole 2,3-dioxygenase (IDO)",42.3736158,-71.1097335,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"136","6311","Joshua","Walker","Oregon Health & Science University","Portland","United States","Alpha-tocopheryloxyacetic acid (aTEA) induced immune activation synergizes with radiation therapy to treat primary and metastatic murine mammary carcinoma",45.5230622,-122.6764816,"TUMOR BIOLOGY","small","immune"
"137","4157","Brynjar","Mauseth","Department of Medical Biology, University of Tromsø","TROMSØ","Norway","The amphiphatic &#946;(2,2)-amino acid derivative, LTX-401 induces complete regression of experimental hepatocellular carcinomas",69.6492047,18.9553238,"IMMUNOLOGY","small","immune"
"138","5642","Kathryn","Fraser","Biothera","Eagan","United States","Imprime PGG synergizes with anti-angiogenic antibodies to repolarize the immune microenvironment, suppressing xenograft tumor growth <i>in vivo</i>",44.8041322,-93.1668858,"TUMOR BIOLOGY","small","immune"
"139","2209","Luigi","Buonaguro","National Cancer Institute","NAPLES","Italy","A novel multidrug metronomic chemotherapy significantly delays tumor growth in mice",40.8517746,14.2681244,"TUMOR BIOLOGY","small","chemotherapy"
"141","3101","Jason","Chesney","University of Louisville","Louisville","United States","Taking the sweet out of Th17 cells to potentiate immuno-oncology drugs",38.2526647,-85.7584557,"IMMUNOLOGY","small combo CPI","immune"
"143","6713","Fatima","Ali-Rahmani","National Cancer Institute","Bethesda","United States","Tyrosine kinase discoidin domain receptor-1 (DDR1) regulates cytotoxicity of recombinant immunotoxin for cancer therapy",38.984652,-77.0947092,"TUMOR BIOLOGY","small","immune"
"144","6771","Jae-Kwan","Lee","Korea University Guro Hospital","Seoul","Korea, Republic of","Clinical application of a natural polypeptide, poly-&#947;-glutamic acid, which has immunotherapeutic efficacy",37.566535,126.9779692,"CLINICAL TRIALS","small","immune"
"145","6924","Wen Min","Lau","Cancer Science Institute of Singapore","Singapore","Singapore","High efficacy of BAY 1187982, an FGFR2-ADC, in overcoming drug resistance in a diffuse type gastric cancer patient-derived xenograft model with acquired resistance to pan-FGFR inhibitor AZD4547",1.3553794,103.8677444,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"146","7014","Kjersti","Flatmark","The Norwegian Radium Hospital, Oslo University Hospital","Oslo","Norway","Novel intraperitoneal treatment for peritoneal metastases: results from the Immunotoxin in Peritoneal Carcinomatosis (ImmunoPeCa) phase I clinical trial",59.9138688,10.7522454,"CLINICAL TRIALS","small","immune"
"147","7079","Jeff","Behrens","Siamab Therapeutics","Newton","United States","Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates (ADCs) demonstrate tumor specificity, unique sequence homology and <i>in vitro</i> and <i>in vivo</i> antitumor efficacy",42.3370413,-71.2092214,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"148","7086","Ohad","Ilovich","inviCRO","Boston","United States","A dual-isotope 3D cryo-imaging quantitative autoradiography (CIQA) method for simultaneous and quantitative assessment of both antibody and drug conjugate tumor distribution and kinetics",42.3600825,-71.0588801,"TUMOR BIOLOGY","ADC",NA
"149","7136","Efrat","Dotan","Fox Chase Cancer Center","Philadelphia","United States","Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results",39.9525839,-75.1652215,"CLINICAL TRIALS","ADC",NA
"150","7216","Scott","Tagawa","Weill Cornell Medicine","New York","United States","Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience",40.7127837,-74.0059413,"CLINICAL TRIALS","ADC",NA
"151","7279","Michelle","Fanale","Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center","Houston","United States","Phase I/Ib study of the novel CD20-targeted immunotoxin MT-3724 in relapsed/refractory non-Hodgkin's B-cell lymphoma",29.7604267,-95.3698028,"CLINICAL TRIALS","small","immune"
"152","7290","Gabor","Gyulveszi","Roche pRED, Roche Innovation Center Zurich","Schlieren","Switzerland","RG70099: A novel, highly potent dual IDO1/TDO inhibitor to reverse metabolic suppression of immune cells in the tumor micro-environment",47.3982611,8.448795,"IMMUNOLOGY","small","immune"
"153","7292","Kohei","Tanaka","Minase Research Institute/Ono Pharmaceutical Co., Ltd.","Osaka","Japan","Development of Axl/Mer inhibitor, ONO-9330547: preclinical evidence supporting the combination with immunotherapeutics",34.6937378,135.5021651,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small combo CPI","oncogenic kinases"
"154","7476","Marie-Priscille","Brun","Sanofi R&D","Vitry-sur-Seine","France","Towards new cryptophycins as promising payloads for ADC",48.792001,2.39851,"CANCER CHEMISTRY","ADC",NA
"155","7495","Khaldoun","Almhanna","Moffitt Cancer Center","Tampa","United States","A phase II trial of TAK-264, a novel antibody-drug conjugate (ADC), in patients with pancreatic adenocarcinoma expressing guanylyl cyclase C (GCC)",27.950575,-82.4571776,"CLINICAL TRIALS","ADC",NA
"156","7718","Katherine","Ferrara","University of California, Davis","Davis","United States","Activatable nanodelivery combined with CpG-ODN and anti-PD-1 achieves a complete response in directly-treated and contralateral tumors in a murine breast cancer model",38.5449065,-121.7405167,"CANCER CHEMISTRY","small combo CPI","chemotherapy"
"157","7763","Robert","Weiss","UC Davis","Davis","United States","Combination therapy of immune checkpoint and nuclear exporter inhibitors in a renal cell carcinoma mouse model",38.5449065,-121.7405167,"IMMUNOLOGY","small combo CPI","other"
"158","7816","Yousef","Zakharia","University of Iowa, Holden Comprehensive Cancer Center","IOWA CITY","United States","Phase II trial of theiIndoleamine 2, 3-dioxygenase pathway (IDO) inhibitor indoximod plus immune checkpoint inhibitors for the treatment of unresectable stage 3 or 4 melanoma",41.6611277,-91.5301683,"CLINICAL TRIALS","small combo CPI","immune"
"159","7821","Adria","Bykowski Jonas","Biothera","Eagan","United States","Imprime PGG drives adaptive immune resistance within the tumor microenvironment by modulating the myeloid compartment and enhances the efficacy of anti-PD1 antibody in vivo",44.8041322,-93.1668858,"IMMUNOLOGY","small combo CPI","immune"
"160","7854","James","Olson","Fred Hutchinson Cancer Center","Seattle","United States","An optide (optimized knottin-peptide) that inhibits tumor cell growth In vitro and accumulates in sarcoma flank tumors in vivo",47.6062095,-122.3320708,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","ADC",NA
"161","7880","Steven","Leonardo","Biothera Pharmaceutical Inc","Eagan","United States","Imprime PGG, a &#946;-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies",44.8041322,-93.1668858,"IMMUNOLOGY","small","immune"
"162","7940","Ross","Fulton","Biothera, Inc.","Eagan","United States","Imprime PGG, a &#946;-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy",44.8041322,-93.1668858,"IMMUNOLOGY","small","immune"
"163","1257","Radhashree","Maitra","Montefiore Medical Center","Bronx","United States","Toll like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer",40.8370495,-73.8654295,"EXPERIMENTAL AND MOLECULAR THERAPEUTICS","small","immune"
"164","2394","Ana Maria","Waaga-Gasser","University of Wuerzburg, Dept. of Surgery I, Molecular Oncology and Immunology","Wuerzburg","Germany","Cancer cell-mediated signaling of TLR 2, 4, and 9 causes activation of PI3K/Akt/mTOR pathway and induces tumor cell proliferation in pancreatic cancer",49.7913044,9.9533548,"IMMUNOLOGY","small","immune"
"165","4062","Ibtehaj","Naqvi","Duke University Medical School","Durham","United States","Toll-like receptor expression and ligation promotes in vitro invasion in pancreatic cancer",35.9940329,-78.898619,"MOLECULAR AND CELLULAR BIOLOGY, GENETICS","small","immune"
"166","5703","Gabriela","Baerlocher","Inselspital/University Hospital of Bern","CH-3010 Bern","Switzerland","Myelosuppression in patients treated with the telomerase inhibitor imetelstat is not mediated through activation of toll-like receptors",46.9475044,7.423628,"MOLECULAR AND CELLULAR BIOLOGY, GENETICS","small","immune"
"167","1320","David","Panka","Beth Israel Deaconess Med Ctr","Boston","United States","Regulation of MDSC trafficking and function in RCC by CXCR4 in the presence of a VEGF-R antagonist",42.3600825,-71.0588801,"TUMOR BIOLOGY","small","immune"
"168","2151","David Kung-Chun","Chiu","The University of Hong Kong","Hong Kong","Hong Kong","Hypoxia as a driver of myeloid-derived suppressor cell recruitment in hepatocellular carcinoma via CCL26/CX3CR1",22.396428,114.109497,"TUMOR BIOLOGY","small","immune"
"170","4466","Sun-Hee","Kim","UT MD Anderson Cancer Center","Houston","United States","Microsomal PGE2 synthase-1 regulates melanoma cell survival and associates with melanoma disease progression",29.7604267,-95.3698028,"CLINICAL RESEARCH","small","immune"
"171","4685","Mariana","Callero","Angel H. Roffo Inst. of Oncology","Buenos Aires","Argentina","Aminoflavone acts as an immunomodulator of tumor growth in a breast cancer mouse model",-34.6036844,-58.3815591,"CLINICAL RESEARCH","small","immune"
"173","3620","Megan","Kaneda","UCSD Moores Cancer Center","La Jolla","United States","Macrophage PI3Kgamma signaling promotes cancer immune suppression",32.8328112,-117.2712717,"TUMOR BIOLOGY","small","leucocyte kinases"
